We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$5.16B
AUM Growth
-$770M
Cap. Flow
-$830M
Cap. Flow %
-16.07%
Top 10 Hldgs %
43.16%
Holding
126
New
20
Increased
28
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$280M
2
MNST icon
Monster Beverage
MNST
+$102M
3
HLT icon
Hilton Worldwide
HLT
+$86.3M
4
DECK icon
Deckers Outdoor
DECK
+$83.7M
5
MAR icon
Marriott International
MAR
+$77.7M

Top Sells

Rank Stock Value
1
TWLO icon
Twilio
TWLO
+$165M
2
ADBE icon
Adobe
ADBE
+$152M
3
MA icon
Mastercard
MA
+$147M
4
PLAN
Anaplan, Inc.
PLAN
+$132M
5
ROST icon
Ross Stores
ROST
+$122M

Sector Composition

Rank Sector Weight
1 Healthcare 35.24%
2 Consumer Discretionary 21.52%
3 Technology 17.66%
4 Industrials 15.63%
5 Consumer Staples 5.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$20.3M 0.39%
1,247,468
+200,000
+19% +$2.85M
CHRS icon
52
Coherus Oncology
CHRS
$196M
$19.5M 0.38%
1,218,792
+729,459
+149% +$12.8M
CMRX
53
DELISTED
Chimerix, Inc.
CMRX
$17.8M 0.34%
2,766,619
+858,999
+45% +$5.15M
IFRX icon
54
InflaRx
IFRX
$271M
$15.6M 0.3%
3,285,000
– –
PNT
55
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$15M 0.29%
2,672,863
+447,863
+20% +$3.36M
MREO
56
Mereo BioPharma
MREO
$47.3M
$14.6M 0.28%
9,142,067
– –
GRAB icon
57
Grab
GRAB
$14.9B
$14.3M 0.28%
+2,000,000
New +$15.3M
SYRE icon
58
Spyre Therapeutics
SYRE
$9.25B
$12.2M 0.24%
102,840
+16,531
+19% +$2.61M
PHVS icon
59
Pharvaris
PHVS
$2.44B
$11.9M 0.23%
+827,540
New +$12.9M
SLDB icon
60
Solid Biosciences
SLDB
$900M
$11M 0.21%
419,146
+20,866
+5% +$638K
BOLT icon
61
Bolt Biotherapeutics
BOLT
$7.78M
$10.9M 0.21%
111,513
+45,238
+68% +$8.59M
DICE
62
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$10.4M 0.2%
410,000
– –
AMAM
63
DELISTED
Ambrx Biopharma Inc
AMAM
$9.55M 0.18%
+1,057,735
New +$11.8M
TERN
64
DELISTED
Terns Pharmaceuticals
TERN
$8.76M 0.17%
1,238,800
+113,064
+10% +$942K
MOLN
65
Molecular Partners
MOLN
$7.67M 0.15%
400,000
– –
SIOX
66
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.63M 0.15%
5,914,000
+425,000
+8% +$754K
INZY
67
DELISTED
Inozyme Pharma
INZY
$6.91M 0.13%
1,013,216
+26,816
+3% +$232K
IRON icon
68
Disc Medicine
IRON
$2.97B
$6.9M 0.13%
79,076
+7,815
+11% +$766K
ROIV icon
69
Roivant Sciences
ROIV
$26.2B
$6.87M 0.13%
+681,528
New +$5.67M
ORIC icon
70
Oric Pharmaceuticals
ORIC
$1.4B
$6.48M 0.13%
440,696
+291,596
+196% +$4.55M
MIST icon
71
Milestone Pharmaceuticals
MIST
$152M
$5.58M 0.11%
851,291
– –
OTIC
72
DELISTED
Otonomy, Inc.
OTIC
$5.57M 0.11%
2,678,115
+290,415
+12% +$597K
ABCL icon
73
CALL
AbCellera Biologics
ABCL
$2.12B
$5.25M 0.1%
+367,100
New +$5.57M
RACB
74
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.88M 0.09%
500,000
– –
ALLO icon
75
Allogene Therapeutics
ALLO
$694M
$3.96M 0.08%
+265,116
New +$4.68M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Suvretta Capital Management held 126 positions worth $5.16B, down 13% from $5.94B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Suvretta Capital Management withdrew a net $830M in Q4 2021, closing 31 positions and reducing 23 holdings. Its most notable exit was Twilio, an estimated $165M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Suvretta Capital Management opened a new position in Microsoft worth $291M.

  • Suvretta Capital Management's largest Q4 2021 buy was Microsoft: 865,000 shares worth $291M.
  • Suvretta Capital Management added most to Analog Devices in Q4 2021, an estimated $60.5M increase.
  • Suvretta Capital Management's biggest Q4 2021 reduction was Adobe, cutting an estimated $152M.
  • Suvretta Capital Management fully exited Twilio in Q4 2021, selling an estimated $165M.
  • Suvretta Capital Management's ten largest holdings make up 43% of its $5.16B portfolio in Q4 2021.
  • Suvretta Capital Management opened 20 new positions and closed 31 in Q4 2021.
  • Suvretta Capital Management's portfolio value fell 13% quarter-over-quarter to $5.16B.

Based on Suvretta Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.